British journal of cancer · 2000

Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD

Аннотация

Although increased bone formation is a prominent feature of patients with osteosclerotic metastases from prostate cancer, there is also some evidence for increased bone resorption. The aim of this study was to compare the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment. Thirty-nine patients with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic hyperplasia and 355 healthy age-matched men were included. Urinary non-isomerized (alpha CTX) and beta isomerized (beta CTX) type I collagen C-telopeptides (CTX) and a new assay for serum CTX were used to assess bone resorption. Bone formation was determined by serum osteocalcin, serum total (T-ALP) and bone (BAP) alkaline phosphatase and serum type I collagen C-terminal propeptide (PICP). Fourteen patients with bone metastases were also evaluated 15 days after a single injection of the bisphosphonate pamidronate (120 mg). Levels of all bone formation and bone resorption markers were significantly (P < 0.006-0.0001) higher in patients with prostate cancer and bone metastasis than in patients with benign prostatic hyperplasia, patients with prostate cancer without bone metastases and healthy controls. In patients with bone metastases the median was increased by 67% for serum osteocalcin, 128% for T-ALP, 138% for BAP, 79% for PICP, 220% for urinary alpha CTX, 149% for urinary beta CTX and 214% for serum CTX. After bisphosphonate treatment all three resorption markers significantly decreased by an average of 65% (P = 0.001), 71% (P = 0.0010) and 61% (P = 0.0015) for urinary alpha CTX, urinary beta CTX and serum CTX, respectively, whereas no significant change was observed for any bone formation markers. Patients with prostate cancer and bone metastases exhibit a marked increase in bone resorption, which decreases within a few days of treatment with pamidronate. These findings suggest that these new resorption markers may be useful for the management of these patients.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Full Text

The Full Text of this article is available as a PDF (115.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Adami S. Bisphosphonates in prostate carcinoma. Cancer. 1997 Oct 15;80(8 Suppl):1674–1679. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1674::aid-cncr18>3.3.co;2-d.

Adami S., Salvagno G., Guarrera G., Bianchi G., Dorizzi R., Rosini S., Mobilio G., Lo Cascio V. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985 Dec;134(6):1152–1154. doi: 10.1016/s0022-5347(17)47663-4.

Akimoto S., Furuya Y., Akakura K., Ito H. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocr J. 1998 Feb;45(1):97–104. doi: 10.1507/endocrj.45.97.

Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M. J. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996 Feb 22;334(8):488–493. doi: 10.1056/NEJM199602223340802.

Berruti A., Piovesan A., Torta M., Raucci C. A., Gorzegno G., Paccotti P., Dogliotti L., Angeli A. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer. 1996 Jun;73(12):1581–1587. doi: 10.1038/bjc.1996.298.

Blom E., Ali M. M., Mortensen B., Huseby N. E. Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates. Clin Chim Acta. 1998 Feb 23;270(2):125–137. doi: 10.1016/s0009-8981(97)00217-9.

Body J. J., Coleman R. E., Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev. 1996 Jul;22(4):265–287. doi: 10.1016/s0305-7372(96)90020-1.

Bonde M., Fledelius C., Qvist P., Christiansen C. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem. 1996 Oct;42(10):1639–1644.

Bonde M., Garnero P., Fledelius C., Qvist P., Delmas P. D., Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res. 1997 Jul;12(7):1028–1034. doi: 10.1359/jbmr.1997.12.7.1028.

Bonde M., Qvist P., Fledelius C., Riis B. J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 1994 Nov;40(11 Pt 1):2022–2025.

Carey P. O., Lippert M. C. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology. 1988 Nov;32(5):403–407. doi: 10.1016/0090-4295(88)90410-4.

Clarke N. W., McClure J., George N. J. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 1992 Jan;69(1):64–70. doi: 10.1111/j.1464-410x.1992.tb15461.x.

Clarke N. W., McClure J., George N. J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991 Jul;68(1):74–80. doi: 10.1111/j.1464-410x.1991.tb15260.x.

Coleman R. E. Monitoring of bone metastases. Eur J Cancer. 1998 Feb;34(2):252–259. doi: 10.1016/s0959-8049(97)10134-4.

Delmas P. D., Demiaux B., Malaval L., Chapuy M. C., Meunier P. J. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int. 1986 Jan;38(1):60–61. doi: 10.1007/BF02556596.

Elomaa I., Kylmälä T., Tammela T., Viitanen J., Ottelin J., Ruutu M., Jauhiainen K., Ala-Opas M., Roos L., Seppänen J. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol. 1992;24(2):159–166. doi: 10.1007/BF02549644.

Engler H., Koeberle D., Thuerlimann B., Senn H. J., Riesen W. F. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clin Chem Lab Med. 1998 Nov;36(11):879–885. doi: 10.1515/CCLM.1998.154.

Fledelius C., Johnsen A. H., Cloos P. A., Bonde M., Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem. 1997 Apr 11;272(15):9755–9763. doi: 10.1074/jbc.272.15.9755.

Garnero P., Fledelius C., Gineyts E., Serre C. M., Vignot E., Delmas P. D. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. J Bone Miner Res. 1997 Sep;12(9):1407–1415. doi: 10.1359/jbmr.1997.12.9.1407.

Garnero P., Gineyts E., Schaffer A. V., Seaman J., Delmas P. D. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum. 1998 Feb;41(2):354–360. doi: 10.1002/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5.

Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., Delmas P. D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res. 1992 Dec;7(12):1389–1398. doi: 10.1002/jbmr.5650071206.

Garnero P., Shih W. J., Gineyts E., Karpf D. B., Delmas P. D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994 Dec;79(6):1693–1700. doi: 10.1210/jcem.79.6.7989477.

Gomez B., Jr, Ardakani S., Ju J., Jenkins D., Cerelli M. J., Daniloff G. Y., Kung V. T. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem. 1995 Nov;41(11):1560–1566.

Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998 Jul;13(7):1124–1133. doi: 10.1359/jbmr.1998.13.7.1124.

Hassager C., Jensen L. T., Pødenphant J., Thomsen K., Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int. 1994 Jan;54(1):30–33. doi: 10.1007/BF00316286.

Hortobagyi G. N., Theriault R. L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J. F., Seaman J., Knight R. D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996 Dec 12;335(24):1785–1791. doi: 10.1056/NEJM199612123352401.

Ikeda I., Miura T., Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol. 1996 Jan;77(1):102–106. doi: 10.1046/j.1464-410x.1996.82817.x.

Koizumi M., Maeda H., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer. 1997;75(11):1601–1604. doi: 10.1038/bjc.1997.273.

Kylmälä T., Tammela T. L., Risteli L., Risteli J., Kontturi M., Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995 May;71(5):1061–1064. doi: 10.1038/bjc.1995.204.

Kylmälä T., Tammela T., Risteli L., Risteli J., Taube T., Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29A(6):821–825. doi: 10.1016/s0959-8049(05)80417-4.

Lorente J. A., Morote J., Raventos C., Encabo G., Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol. 1996 Apr;155(4):1348–1351.

Maeda H., Koizumi M., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997 Feb;157(2):539–543.

Miyamoto K. K., McSherry S. A., Robins S. P., Besterman J. M., Mohler J. L. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol. 1994 Apr;151(4):909–913. doi: 10.1016/s0022-5347(17)35120-0.

Nakashima J., Sumitomo M., Miyajima A., Jitsukawa S., Saito S., Tachibana M., Murai M. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol. 1997 May;157(5):1736–1739.

Nguyen-Pamart M., Caty A., Feutrie M. L., Fournier C., Gosselin P., Mazeman E. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer. Br J Urol. 1997 Sep;80(3):452–455. doi: 10.1046/j.1464-410x.1997.00375.x.

Pecherstorfer M., Zimmer-Roth I., Schilling T., Woitge H. W., Schmidt H., Baumgartner G., Thiébaud D., Ludwig H., Seibel M. J. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995 Jan;80(1):97–103. doi: 10.1210/jcem.80.1.7829646.

Pelger R. C., Hamdy N. A., Zwinderman A. H., Lycklama à Nijeholt A. A., Papapoulos S. E. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone. 1998 Apr;22(4):403–408. doi: 10.1016/s8756-3282(97)00289-5.

Pollen J. J., Witztum K. F., Ashburn W. L. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol. 1984 Apr;142(4):773–776. doi: 10.2214/ajr.142.4.773.

Price P. A., Williamson M. K., Lothringer J. W. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981 Dec 25;256(24):12760–12766.

Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640.

Rosenquist C., Fledelius C., Christgau S., Pedersen B. J., Bonde M., Qvist P., Christiansen C. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998 Nov;44(11):2281–2289.

Sano M., Kushida K., Takahashi M., Ohishi T., Kawana K., Okada M., Inoue T. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer. 1994 Oct;70(4):701–703. doi: 10.1038/bjc.1994.377.

Smedsrød B., Melkko J., Risteli L., Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J. 1990 Oct 15;271(2):345–350. doi: 10.1042/bj2710345.

Soloway M. S., Hardeman S. W., Hickey D., Raymond J., Todd B., Soloway S., Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195–202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y.

Takeuchi S., Arai K., Saitoh H., Yoshida K., Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol. 1996 Nov;156(5):1691–1695.

Taube T., Kylmälä T., Lamberg-Allardt C., Tammela T. L., Elomaa I. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. Eur J Cancer. 1994;30A(6):751–758. doi: 10.1016/0959-8049(94)90287-9.

Uebelhart D., Gineyts E., Chapuy M. C., Delmas P. D. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 1990 Jan;8(1):87–96. doi: 10.1016/0169-6009(91)90143-n.

Urwin G. H., Percival R. C., Harris S., Beneton M. N., Williams J. L., Kanis J. A. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 1985 Dec;57(6):721–723. doi: 10.1111/j.1464-410x.1985.tb07040.x.

Vinholes J. J., Purohit O. P., Abbey M. E., Eastell R., Coleman R. E. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997 Dec;8(12):1243–1250. doi: 10.1023/a:1008238422151.

Vinholes J., Guo C. Y., Purohit O. P., Eastell R., Coleman R. E. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer. 1996 May;73(9):1089–1095. doi: 10.1038/bjc.1996.210.

Yoshida K., Sumi S., Arai K., Koga F., Umeda H., Hosoya Y., Honda M., Yano M., Moriguchi H., Kitahara S. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer. 1997 Nov 1;80(9):1760–1767.

Young G. P., Rose I. S., Cropper S., Seetharam S., Alpers D. H. Hepatic clearance of rat plasma intestinal alkaline phosphatase. Am J Physiol. 1984 Oct;247(4 Pt 1):G419–G426. doi: 10.1152/ajpgi.1984.247.4.G419.

Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Ошибки и ограничения

Аннотация

Full Text

Selected References